CDK 4/6 inhibitors (CDKi) + endocrine therapy (ET) in ER-positive metastatic breast cancer (mBC) patients according ET sensitivity: A systematic review and meta-analysis.

Michela Piezzo,Maria Riemma,Daniela Cianniello,Roberta Caputo,Giuseppina Fusco,Germira Di Gioia,Ivana Cerillo,Marina Licenziato,G. Buonfanti,Stefania Cocco,Vincenzo Di Lauro,Michelino De Laurentiis

CDK 4/6 inhibitors (CDKi) + endocrine therapy (ET) in ER-positive metastatic breast cancer (mBC) patients according ET sensitivity: A systematic review and meta-analysis.

2019

Michela Piezzo
Maria Riemma
Daniela Cianniello
Roberta Caputo
Giuseppina Fusco
Germira Di Gioia
Ivana Cerillo
Marina Licenziato
G. Buonfanti
Stefania Cocco
Vincenzo Di Lauro
Michelino De Laurentiis

e12532Background: Addition of CDKi to ET in ER-positive mBC has proven effective in improving both progression-freesurvival (PFS) and Objective Response Rate (ORR). However, no randomized clinical ...

Keywords:

Meta-analysis
Oncology
Response rate (survey)
Endocrine system
Pathology
Cyclin-dependent kinase
Internal medicine
Metastatic breast cancer
Medicine
objective response
endocrine therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations